Dennis Fenton Net Worth

The estimated Net Worth of Dennis M Fenton is at least $4.96 Million dollars as of 21 June 2024. Dennis Fenton owns over 1,950 units of AnaptysBio Inc stock worth over $69,420 and over the last 21 years he sold ANAB stock worth over $4,571,625. In addition, he makes $318,986 as Independent Director at AnaptysBio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dennis Fenton ANAB stock SEC Form 4 insiders trading

Dennis has made over 7 trades of the AnaptysBio Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 1,950 units of ANAB stock worth $45,182 on 21 June 2024.

The largest trade he's ever made was selling 40,320 units of AnaptysBio Inc stock on 31 July 2003 worth over $2,839,334. On average, Dennis trades about 1,722 units every 121 days since 2003. As of 21 June 2024 he still owns at least 1,950 units of AnaptysBio Inc stock.

You can see the complete history of Dennis Fenton stock trades at the bottom of the page.

Dennis Fenton biography

Dr. Dennis Fenton Ph.D. serves as Independent Director of the Company. From 1981 to 2008, Dr. Fenton held numerous positions at Amgen, Inc., a biotechnology company, including Executive Vice President from 2000 until 2008, Senior Vice President of Operations from 1995 until 2000 and Senior Vice President of Sales, Marketing and Process Development from 1992 until 1995. Prior to his time at Amgen, Inc., Dr. Fenton served as Senior Research Scientist at Pfizer, Inc., and previously was a research associate and graduate student at Rutgers University. Dr. Fenton currently serves on the board of directors of Sienna Biopharmaceuticals, Portola Pharmaceuticals, and Pfenex Inc. He previously served on the boards of directors of XenoPort, Inc. and Kythera Biopharmaceuticals, Inc., as well as several private company boards. Dr. Fenton holds a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University. Our board of directors believes that Dr. Fenton’s extensive experience in the life sciences industry provides him with the qualifications and skills to serve on our board of directors.

What is the salary of Dennis Fenton?

As the Independent Director of AnaptysBio Inc, the total compensation of Dennis Fenton at AnaptysBio Inc is $318,986. There are 6 executives at AnaptysBio Inc getting paid more, with Hamza Suria having the highest compensation of $7,875,190.

How old is Dennis Fenton?

Dennis Fenton is 68, he's been the Independent Director of AnaptysBio Inc since 2018. There are 1 older and 13 younger executives at AnaptysBio Inc. The oldest executive at AnaptysBio Inc is Hollings Renton, 73, who is the Lead Independent Director.

What's Dennis Fenton's mailing address?

Dennis's mailing address filed with the SEC is C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121.

Insiders trading at AnaptysBio Inc

Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1, and James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.

What does AnaptysBio Inc do?

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c

Complete history of Dennis Fenton stock trades at AMGEN, AnaptysBio Inc, Portola Pharmaceuticals, and Pfenex

AnaptysBio Inc executives and stock owners

AnaptysBio Inc executives and other stock owners filed with the SEC include:

• Hamza Suria,
  President, Chief Executive Officer, Director
• Eric Loumeau,
  Chief Operating Officer, General Counsel
• Hamza Suria,
  Pres, CEO & Director
• Dennis M. Mulroy,
  Chief Financial Officer
• Dr. Paul F. Lizzul,
  Chief Medical Officer
• James Topper,
  Independent Chairman of the Board
• Dennis Fenton,
  Independent Director
• Hollings Renton,
  Lead Independent Director
• J. Anthony Ware,
  Independent Director
• John Schmid,
  Independent Director
• Laura Hamill,
  Independent Director
• Paul Lizzul,
  Chief Medical Officer
• Dennis Mulroy,
  Chief Financial Officer
• Eric J. Loumeau,
  COO & Gen. Counsel
• David McKeon,
  VP & Controller
• Dr. Margaret Marino,
  Sr. VP of Project Management
• Beth Mueller,
  Sr. VP of HR
• Nicholas Lydon,
  Director
• Carol Giltner Gallagher,
  Director
• Matthew Moyle,
  Chief Scientific Officer
• James A Schoeneck,
  Director
• Dominic Piscitelli,
  Chief Financial Officer
• Marco Londei,
  Chief Medical Officer
• Healthcare Vii, L.P.Frazier...,
  
• Healthcare V, Lpfhm V, Lpfh...,
  
• Holdings A/S Novo,
  10% owner
• Ventures Vii L Pavalon Vent...,
  
• John A Orwin,
  
• Magda Marquet,
  
• Rita Jain,
  
• Capital, Llcnodelman Oleg E...,
  
• Capital, Llc Eco R1,
  10% owner
• Daniel Faga,
  CEO